Related Content
- FDA OKs Abilify as maintenance treatment for bipolar disorder
- FDA gives Wockhardt tentative approval for bipolar, schizophrenia drug
- Merck: FDA approves Oxytrol for Women, creating overactive bladder category in OTC
- Reports: Otsuka can block Apotex's generic version of Abilify
- New alliance will crack down on adulterated products touting dietary supplement claims
TOKYO — The Food and Drug Administration has approved a once-monthly treatment for schizophrenia.
Otsuka Pharmaceutical and H. Lundbeck announced the FDA approval of Abilify Maintena (aripiprazole) for extended-release injectable suspension, an intramuscular depot formulation indicated for the treatment of schizophrenia.
The companies described Abilify Maintena as the first dopamine D2 partial agonist approved as a once-monthly injection, contributing to a new treatment option to address the ongoing need for relapse prevention in patients with schizophrenia.
